Nov 2, 2026 · 1h 8m
Amy Burroughs turned biotech uncertainty into negotiating power
How to Negotiate From a Position of Power: Amy Burroughs on Merck, Leverage & Leadership
The conversation shows how strategic focus, execution, and a credible willingness to walk away can shape a multibillion-dollar outcome.
- 1Burroughs built leverage by advancing Terns’ strongest program while preserving a viable standalone path.
- 2Terns chose leukemia over a fashionable obesity market, prioritizing competitive advantage over hype.
- 3Effective leadership depended on complementary teams, trusted sponsors, and emotional distance during high-stakes decisions.
Don't miss
Burroughs explains why maintaining the option to reject Merck’s offer was central to creating negotiating leverage.
The brief
Amy Burroughs traces a nonlinear route through technology, healthcare, executive search, venture capital, and biotech leadership, guided more by curiosity than a fixed career plan.
At Terns Pharmaceuticals, she chose leukemia over the hot obesity market, arguing that companies should concentrate resources where their competitive advantages are strongest.
The $6.7 billion Merck acquisition emerged from execution, clinical data, relationships, and competing interest—but leverage depended on preserving a credible path to remain independent.
Burroughs describes staying calm through diligence and bidding while keeping the team focused on advancing the drug, rather than becoming emotionally attached to a sale.
The interview widens into a leadership philosophy built on complementary teams, sponsorship, personal support, and making room for uncertainty after a major success.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.